NASDAQ:EXEL Exelixis Q3 2026 Earnings Report $58.36 -0.49 (-0.83%) As of 10:56 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Exelixis EPS ResultsActual EPSN/AConsensus EPS $0.88Beat/MissN/AOne Year Ago EPSN/AExelixis Revenue ResultsActual RevenueN/AExpected Revenue$647.90 millionBeat/MissN/AYoY Revenue GrowthN/AExelixis Announcement DetailsQuarterQ3 2026Date11/3/2026TimeAfter Market ClosesConference Call DateTuesday, November 3, 2026Conference Call Time5:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Exelixis Earnings HeadlinesExelixis (NASDAQ:EXEL) Sets New 1-Year High - Here's WhyOctober 2, 2026 | americanbankingnews.comExelixis stock hits all-time high at 59.73 USDOctober 1, 2026 | au.investing.comNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire year. The top five hyperscalers, Amazon, Google, Microsoft, Meta, and Oracle, are projected to spend 800 billion on AI this year and 1.3 trillion next year. Jason Bodner, a former Wall Street trader whose system has flagged stocks like Nvidia, Super Micro Computer, and Vertiv before major run ups, says a new light speed technology called Accelerated AI could be next in line for that spending.October 6 at 1:00 AM | Brownstone Research (Ad)Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?September 17, 2026 | insidermonkey.comAnalysts Offer Insights on NA Companies: Exelixis (EXEL) and Resolution Minerals Ltd. Sponsored ADR (RML)September 15, 2026 | theglobeandmail.comExelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comSee More Exelixis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Exelixis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exelixis and other key companies, straight to your email. Email Address About ExelixisExelixis (NASDAQ:EXEL) is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer. The company’s research and development activities are centered primarily on targeted therapies and other treatments for solid tumors. Exelixis’ principal product is cabozantinib, marketed in the United States as CABOMETYX tablets for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. The company also markets COMETRIQ, a cabozantinib formulation approved in the United States for progressive or metastatic medullary thyroid cancer. Exelixis was founded in 1994 and is headquartered in Alameda, California. Its medicines are marketed internationally through a combination of direct commercial activities and collaborations, including partnerships that support the availability of cabozantinib in markets outside the United States. The company continues to advance a pipeline of oncology candidates, including investigational therapies designed to address additional tumor types and treatment settings. Michael M. Morrissey has served as Exelixis’ president and chief executive officer since 2010. The company’s common stock trades on the Nasdaq under the symbol EXEL.View Exelixis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
